Coding

Part:BBa_K4739011:Design

Designed by: Huaiyuan Ma   Group: iGEM23_SUSTech-Shenzhen   (2023-10-11)


KLA, a pro-apoptotic experimental peptide drug in cancer threapy


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    INCOMPATIBLE WITH RFC[12]
    Illegal NheI site found at 15
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


Design Notes

1. Choose codons that are frequently used in the host organism to ensure efficient translation. 2. Optimize for codons corresponding to abundant tRNAs in the host to enhance translation speed. 3. Limit repetitive DNA sequences that may lead to recombination events and genomic instability.



Source

The sequence of this drug is designed upon its amino acid sequence.

References

1. Huang, Y.; Li, X.; Sha, H.; Zhang, L.; Bian, X.; Han, X.; Liu, B. Tumor-Penetrating Peptide Fused to a Pro-Apoptotic Peptide Facilitates Effective Gastric Cancer Therapy. Oncology Reports 2017, 37, 2063–2070, doi:https://doi.org/10.3892/or.2017.5440.